Skip to main content

Psyence Group Jamaica Chief Medical Officer Dr. Dingle Spence to Headline Two Conferences on Psychedelics

Written by Customer Service on . Posted in Public Companies.

TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Dr. Dingle Spence, the Chief Medical Officer of the Company’s wholly owned subsidiary, Psyence Jamaica Limited, will be a featured speaker at two virtual global conferences, back-to-back this week.

Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.

“Building access to palliative care and providing effective natural psychedelic medicines is at the heart of our work,” noted Psyence Group’s CEO Dr. Neil Maresky who added, “We are proud to support Dr. Dingle Spence in her efforts to ensure equity and innovation as she brings our work at Psyence to the international psychedelic conversation, first at EndWell and then at the Fantastic Fungi Global Summit.”

The first-ever global gathering on psychedelic medicine and palliative care, “The End in Mind” conference is a free, virtual convening that brings together academic researchers, policymakers, entrepreneurs, funders, clinicians, and cultural luminaries. Dr. Spence speaks at 12:45 p.m. EDT on Thursday, Oct.14, in conversation with author Claire Bidwell Smith. They are to be featured alongside the CNN personality Van Jones, the singer Melissa Etheridge, psychedelic maverick Rick Doblin, founder of MAPS, the Multidisciplinary Association for Psychedelic Studies, and the Oscar-nominated physician and public intellectual, Shoshana Ungerleider, MD. Registration is free: https://endwellproject.org/the-end-in-mind/

Just a day later, Dr. Spence joins the New York Times writer and best-selling author Michael Pollan and the iconic mushroom pioneer Paul Stamets in speaking at the 3 day-long “Fantastic Fungi Global Summit,” Dr. Spence’s interview, will be broadcast on Friday, October 15th at 9 p.m. EDT. The Fantastic Fungi Global Summit is a weekend-long virtual summit hosted by Louie Schwartzberg, the award-winning filmmaker behind the top-rated film, Fantastic Fungi. Dr. Andrew Weil and Dr. Deepak Chopra are among the healers who will join Dr. Spence in speaking about psilocybin mushrooms and the future of psychedelic medicines. Registration is free: https://fungiglobalsummit.com

Psyence leads the way in natural psilocybin and other psychedelics for the healing of psychological trauma and its mental health consequences in the context of palliative care. The name “Psyence” combines the words psychedelic and science to affirm a commitment to producing psychedelic medicines developed through evidence-based research.  Dr. Spence, BSc, MBBS, DMRT, Dip Pall. Med, FRCR is a physician with training in both Clinical Oncology and Palliative Medicine. In addition to serving as Psyence Jamaica’s Chief Medical Officer, she is the Senior Medical Officer of the Hope Institute Hospital, Jamaica’s only dedicated oncology and palliative care unit. She is also on the faculty of the Department of Medicine at the University Hospital of the West Indies in Kingston, Jamaica. Dr. Spence has served as Scientific Advisor to the Lancet Commission in Global Access to Palliative Care and Pain Relief and is on both the International Association for Hospice and Palliative Care Board of Directors and the Advisory Board of the EndwellProject.org.

ABOUT PSYENCE GROUP: www.psyence.com

Psyence, a public life science biotechnology company listed on the Canadian Securities Exchange (CSE: PSYG), sets the global standard for natural psychedelics. Our team brings international experience in both business and science and includes experts in mycology, neurology, and drug development.  We work to develop advanced psilocybin products and other psychedelic breakthroughs for research institutes, clinics, therapeutic immersions, and destination experiences for clinical research. We are also developing a nutraceutical mental wellness collection that supports improved focus, calm, and sleep. 

Informed by nature and guided by science, Psyence built and operate one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities.

Our four key divisions (Psyence Production, Psyence Therapeutics, Psyence Function, and Psyence Experience) anchor an international footprint with operations in Canada, United States, United Kingdom, Jamaica, South Africa, and Australia.

Contact Information:
Lisa-Marie Iannitelli, Investor Relations
Email: ir@psyence.com

Media Inquiries: media@psyence.com
General Information: info@psyence.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.